GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer
January 11 2022 - 9:00AM
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company specializing in developing human vaccines and
cancer immunotherapies, today announced the appointment of Kelly T.
McKee, Jr., M.D., M.P.H., to serve as the Company’s Chief Medical
Officer (CMO).
Dr. McKee brings over 30 years of experience in research and
development, with specific expertise in vaccines, emerging
diseases, biodefense, and respiratory viral infections. His
progressive clinical research experience began in 1981 at Fort
Detrick, Frederick, MD, United States, where he held a variety of
leadership positions in virology, immunology, preventive medicine,
and clinical research and development with the U.S. Army, retiring
as a Colonel in 2001. Dr. McKee subsequently served as State
Epidemiologist in North Carolina, and as Senior Director of
Clinical Research at DynPort Vaccine Company. He then held multiple
leadership roles, including Vice President and Managing Director of
Public Health and Government Services, and Vice President for
Vaccines and Public Health in the Infectious Diseases and Vaccines
Center of Excellence, at Quintiles/QuintilesIMS (now IQVIA) for
more than 10 years. He now provides contract clinical development
services to biopharmaceutical industry in infectious diseases and
related areas.
Dr. McKee earned an M.D. from the University of
Virginia School of Medicine, and a Master of Public Health degree
from Johns Hopkins University School of Hygiene and Public Health
in Baltimore, MD. Over the course of a successful military and
private-sector career, he has also earned multiple board and
advisory appointments, certifications, grants, civilian honors, and
inductions and fellowships to some of the world’s most prestigious
medical associations. He has authored or co-authored more than 100
peer-reviewed publications and book chapters.
David Dodd, GeoVax President and CEO, commented,
“Dr. McKee’s addition to our team represents an important step
forward in the strengthening of GeoVax’s organizational and
operational resources to support our advancement through clinical
development and regulatory registration. We are excited to leverage
the wealth of knowledge, expertise, and insights he brings to the
table.”
“I am pleased to be joining the GeoVax team,” said
Dr. McKee. “Infectious disease and vaccine research and development
is my passion and I look forward to engaging with our clinical
researchers, regulatory authorities, and the medical community at
large, to advance GeoVax’s mission of helping create a healthier
world.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines and immunotherapies
against infectious diseases and cancer using novel proprietary
platforms. GeoVax’s product pipeline includes two ongoing Phase 2
clinical trials of GEO-CM04S1 (formerly COH04S1) for COVID-19 as a
universal booster vaccine to mRNA vaccines authorized by the U.S.
Food and Drug Administration (FDA) and as a primary vaccine for use
in immunocompromised patients. In addition to GEO-CM04S1 for
COVID-19, GeoVax is developing GEO-CM02 as a pan-coronavirus
vaccine. The Company is also conducting a Phase 1/2 clinical trial
of Gedeptin® for treatment of head and neck cancer. Gedeptin® has
been granted orphan drug status by the FDA. Additional research and
development programs include preventive vaccines against Zika
Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa)
and malaria, as well as immunotherapies for multiple solid tumors.
The Company’s portfolio of wholly owned, co-owned, and in-licensed
intellectual property stands at over 70 granted or pending patent
applications spread over 20 patent families.
For additional information about GeoVax, visit our
website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements
regarding GeoVax’s business plans. The words “believe,” “look
forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventive vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventive vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventive vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventive vaccines will receive regulatory approvals necessary to
be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is
contained in our registration statement on Form S-3 and the
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by U.S.
federal securities law.
GeoVax Labs, Inc. 6783847220 investor@geovax.com
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Aug 2024 to Sep 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Sep 2023 to Sep 2024